started · updated
Isomorphic Labs raises $5 billion for AI drug discovery
Isomorphic Labs, an Alphabet-owned AI drug discovery company, has secured $5 billion in a Series C funding round. The investment was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and existing backers including Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund.
The capital is intended to advance the company’s proprietary Isomorphic Labs Drug Design Engine (IsoDDE). This platform utilizes foundational simulation AI models to predict molecular behavior and accelerate the identification of target protein binding pockets. The company aims to use the funds to mature its drug pipeline, specifically targeting oncology and immunology, and to build scalable AI-first clinical development infrastructure.
Led by CEO Sir Demis Hassabis, the London-based firm reported positive preclinical results from its internal and partnered programs. The company plans to expand its global bioengineering infrastructure and partner ecosystem to move therapeutic candidates toward human clinical trials.
Entities
Alphabet · Alphabet Inc. · Demis Hassabis · Greenoaks · Isomorphic Labs · Sequoia Capital